1. The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study
   Marco Punta et al, 2020, Frontiers in Immunology CrossRef
2. Prospects for a personalized peptide vaccine against lung cancer
   Yoshiro Nakahara et al, 2019, Expert Review of Vaccines CrossRef
3. In Non-Small Cell Lung Cancer, Can Radiomic Features Predict EGFR Mutations?
   Jiayan Liu et al, 2019, 2019 IEEE International Conference on Mechatronics and Automation (ICMA) CrossRef
4. Endoplasmic Reticulum-Associated Degradation-Dependent Processing in Cross-Presentation and Its Potential for Dendritic Cell Vaccinations: A Review
   Jun Imai et al, 2020, Pharmaceutics CrossRef
5. DMU-212 against EGFR-mutant non-small cell lung cancer via AMPK/PI3K/Erk signaling pathway
   Xiao-Ping Zhao et al, 2023, Heliyon CrossRef
6. Expansion of tumor-infiltrating lymphocytes in non-small cell lung cancer: Clinical potential and efficacy in EGFR mutation subsets
   Hyun Lee et al, 2024, Clinical Immunology CrossRef
7. Deep CNN Model Using CT Radiomics Feature Mapping Recognizes EGFR Gene Mutation Status of Lung Adenocarcinoma
   Baihua Zhang et al, 2021, Frontiers in Oncology CrossRef
8. Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment
   Tetsuro Sasada et al, 2016, Frontiers in Pharmacology CrossRef
9. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non–small cell lung cancer
   Yu Akazawa et al, 2020, Cancer Science CrossRef
10. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential
    Gregory T. Wurz et al, 2016, Therapeutic Advances in Medical Oncology CrossRef
11. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
    J. Remon et al, 2018, Annals of Oncology CrossRef
12. Paraneoplastic Hypomyopathic Dermatomyositis Associated With EGFR Exon-20 Insertion NSCLC
    Connie S. Zhong et al, 2019, Journal of Thoracic Oncology CrossRef
13. Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy
    Xianda Zhao et al, 2018, Pharmacology & Therapeutics CrossRef
14. Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1
    Di Wu et al, 2020, Frontiers in Immunology CrossRef
15. Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma
    Fenge Li et al, 2023, Vaccines CrossRef
16. The antitumor activity screening of chemical constituents from Camellia nitidissima Chi
    Xiaoying Hou et al, 2018, International Journal of Molecular Medicine CrossRef
17. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
    J. Gao et al, 2019, Clinical and Translational Oncology CrossRef